期刊文献+

利奈唑胺治疗骨科患者术后耐药革兰阳性菌感染的疗效观察及安全性分析 被引量:18

Efficacy and safety of linezolid in treatment of postoperative drug-resistant gram-positive bacteria infections in patients of orthopedics department
原文传递
导出
摘要 目的探讨利奈唑胺治疗骨科患者术后耐药革兰阳性菌感染的临床疗效与安全性。方法回顾性分析2013年3月-2015年9月采用利奈唑胺治疗骨科术后耐药革兰阳性菌感染的86例患者的临床资料,分析利奈唑胺治疗后临床效果及不良反应。结果 86例骨科患者术后感染检出病原菌均为耐药革兰阳性菌,主要为金黄色葡萄球菌、表皮葡萄球菌和凝固酶阴性葡萄球菌,分别占44.19%、25.58和17.44%;均使用利奈唑胺药物进行抗感染治疗,治疗总有效率为96.51%,治疗起效时间为3~10d;其中52例患者是直接采用利奈唑胺治疗,用药后48例患者的病原菌被清除,清除率为92.31%,另有34例患者在采用万古霉素治疗无效或不耐受后换用利奈唑胺进行治疗,用药后有25例患者的病原菌被清除,清除率为73.53%;治疗过程中共11例患者出现不良反应,发生率为12.79%。结论临床上采用利奈唑胺治疗骨科术后耐药革兰阳性菌感染的治疗效果明显,不良反应较少。 OBJECTIVE To explore the clinical efficacy and safety of linezolid in treatment of postoperative drug-resistant gram-positive bacteria infections in patients of orthopedics department.METHODS The clinical data of 86 patients with postoperative drug-resistant gram-positive bacteria infections who were treated with linezolid in the orthopedics department from Mar 2013 to Sep 2015 were retrospectively analyzed,and the clinical therapeutic effect and adverse reactions were observed.RESULTS All of the pathogens isolated from the 86 orthopedics department patients with postoperative infections were drug-resistant gram-positive bacteria,among which the Staphylococcus aureus,Staphylococcus epidermidis,and coagulase-negative Staphylococcus were dominant,accounting for 44.19%,25.58%,and 17.44%,respectively.Linezolid was used for treatment of all the patients with the infections,the total effective rate of treatment was 96.51%,the onset time of treatment ranged between 3and 10 days.Totally 52 patients were directly treated with linezolid,the pathogens in 48 patients were eliminated after the drug therapy for 48 hours,with the clearance rate 92.31%;while 34 patients were treated with linezolid by replacing vancomycin due to ineffective treatment or intolerance,and the pathogens in 25 patients were eliminated,with the clearance rate 73.53%.Totally 11 patients had adverse reactions during the treatment,with the incidence rate12.79%.CONCLUSIONThe clinical use of linezolid can achieve significant effect on treatment of the postoperative drug-resistant gram-positive bacteria infections in the orthopedics department,and the incidence of adverse reactions is low.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2016年第17期3984-3986,共3页 Chinese Journal of Nosocomiology
基金 山东省自然科学基金资助项目(0800050069)
关键词 利奈唑胺 耐药革兰阳性菌 感染 骨科 Linezolid Drug-resistant gram-positive bacteria Infection Orthopedics department
  • 相关文献

参考文献10

二级参考文献176

  • 1Fluckiger U, Widmer A F. Epidemiology of methicillin- resistant Staphylococcus aureus[J]. Chemotherapy, 1999, 45(2): 121-134.
  • 2Jones R N, Low D E, Pfaller M A. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: The role of streptogramins and other newer compounds[J]. Diagn Microbiol lnfect Dis, 1999, 33(2): 101-112.
  • 3Herold B C, Immergluck L C, Maranan M C, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk[J]. JAMA, 1998, 279(8): 593-598.
  • 4Richards M J, Edwards J R, Culver D H, et al. Nosocomial infections in combined medical-surgical intensive care anits in the United States[J]. Infect Control Hosp Epidemiol, 2000, 21(8): 510-515.
  • 5Vincent J L, Bihari D J, Surer P M, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee[J]. JAMA, 1995, 274(8): 639-644.
  • 6Fridkin S K, Hill H A, Volkova N V, et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals[J]. Emerg Infect Dis, 2002, 8(7): 697-701.
  • 7Carbon C. Costs of treating infections caused by methicillin- resistant staphylococci and vancomycin-resistant enterococci[J]. JAntimicrob Chemother, 1999, 44 (suppl A): 31-36.
  • 8Engemann J J, Carmeli Y, Cosgrove S E, et al. Adverseclinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection[J]. Clin Infect Dis, 2003, 36(5): 592-598.
  • 9Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility[J]. J Antimicrob Chemother, 1997, 40(1): 135-136.
  • 10Centers for Disease Control and Prevention(CDC). Reduced susceptibility of Staphylococcus aureus to vancomycin- Japan, 1996. MMWR Morb Mortal Wkly Rep, 1997, 46(27): 624-626.

共引文献76

同被引文献127

引证文献18

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部